

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the “Announcement in Relation to the Approval of Drug Clinical Trial of a Subsidiary” published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Yuqing

Chairman

Shanghai, the PRC

14 April 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* for identification purposes only

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Announcement in Relation to the Approval of Drug Clinical Trial of a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Recently, Fosun Kairos (Shanghai) Biological Technology Co., Ltd.* (復星凱瑞(上海)生物科技有限公司) and its subsidiaries (“**Fosun Kairos**”), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥(集團)股份有限公司) (the “**Company**”) received the approval from the National Medical Products Administration for the Phase I/II clinical trial of FKC289 Injection (“**FKC289**”) for the treatment of (1) relapsed/refractory primary light chain amyloidosis; (2) relapsed/refractory membranous nephropathy respectively. Fosun Kairos intends to commence the relevant clinical researches of the drug in China¹ when the conditions are fulfilled.

II. Basic Information and Research Progress on FKC289

FKC289 is a genetically - modified CAR - T cell product that targets BCMA and CD19, which is intended for the treatment of (1) relapsed/refractory primary light chain amyloidosis; (2) relapsed/refractory membranous nephropathy.

FKC289 effectively inhibits the progression of the diseases by simultaneously targeting two different surface antigens, BCMA and CD19, to achieve a profound depletion of pathogenic plasma cells and B cells. It is anticipated to be effective in the treatment of plasma cell diseases and B - cell - mediated autoimmune diseases.

¹ excluding Hong Kong, Macau and Taiwan for the purpose of this announcement, the same applies below.

As of March 2026, the Group (i.e., the Company and its subsidiaries/units) has invested approximately RMB59 million (unaudited) in total in the research and development (“R&D”) of FKC289 at this stage.

As of the date of this announcement (i.e.,14 April 2026), no therapeutic products with the same molecular mechanism have been approved for marketing globally.

III. Impact on the Listed Company and Risk Warning

As required by the relevant laws and regulations in China, the FKC289 is subject to undergo a series of clinical studies and approval by the relevant national drug review department in China before it can be launched. There are certain risks in the R&D of drugs based on our experience. For example, clinical trials may be terminated due to issues such as safety and/or efficacy.

The R&D and launch of drugs is a long-term task involving various uncertainties. Investors should take note of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

14 April 2026

*For identification purpose only